Ignite Creation Date:
2025-12-25 @ 1:23 AM
Ignite Modification Date:
2026-01-06 @ 9:20 PM
Study NCT ID:
NCT04609293
Status:
UNKNOWN
Last Update Posted:
2020-10-30
First Post:
2020-10-26
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Observational Study of Camrelizumab Combined With Apatinib and Hyperfractionated Radiotherapy for Renal Cell Carcinoma
Sponsor:
Peking University First Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-10-20
Start Date Type:
ESTIMATED
Primary Completion Date:
2023-09-07
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-05-07
Completion Date Type:
ESTIMATED
First Submit Date:
2020-10-26
First Submit QC Date:
None
Study First Post Date:
2020-10-30
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-10-26
Last Update Post Date:
2020-10-30
Last Update Post Date Type:
ACTUAL